| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… |
Trial sites expanded: 111 -> 116 locations |
| 2026-06-11 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 18 -> 27 locations |
| 2026-06-06 | NCT05438043 A Study of Daratumumab |
date change Completion pushed: 2029-01-31 -> 2029-12-31 |
| 2026-06-06 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites reduced: 278 -> 271 locations |
| 2026-06-04 | NCT04430894 KRDI in Transplant-Eligible MM |
date change Completion pushed: 2026-03-30 -> 2026-12-30 |
| 2026-06-03 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 12 -> 18 locations |
| 2026-06-02 | NCT05434689 COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide |
date change Primary completion pushed: 2026-04 -> 2028-08 |
| 2026-06-02 | NCT05434689 COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide |
date change Completion pushed: 2026-10 -> 2028-08 |
| 2026-05-28 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Primary completion pushed: 2023-11-08 -> 2026-09-11 |
| 2026-05-28 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
date change Completion pushed: 2023-11-08 -> 2026-09-11 |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Recruitment opened |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
Trial sites expanded: 0 -> 4 locations |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Primary completion moved earlier: 2029-06-29 -> 2028-10-31 |
| 2026-05-28 | NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… |
date change Completion pushed: 2032-12-31 -> 2033-01-31 |
| 2026-05-16 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 6 -> 10 locations |
| 2026-05-15 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites expanded: 131 -> 279 locations |
| 2026-05-15 | NCT07479979 Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With… |
Recruitment opened |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
Trial terminated |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
critical why stopped: null → "Other - Drug supply issues and withdrawal of company support." |
| 2026-05-14 | NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With… |
Enrollment reduced: 36 -> 19 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-26 | NCT07605416 Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants… | Multiple Myeloma | Recruiting |
| NCT07555938 | Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in… | Multiple Myeloma | Recruiting |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT06615479 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in… | Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT05438043 | A Study of Daratumumab | Multiple Myeloma | Recruiting |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… | Multiple Myeloma | Recruiting |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… | Relapsed Refractory Multiple Myeloma | Recruiting |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After… | Multiple Myeloma | Active, Not Recruiting |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and… | Multiple Myeloma | Active, Not Recruiting |
| NCT05552976 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone… | Relapsed or Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone… | Relapsed or Refractory Multiple Myeloma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT04310930 | Finding the Optimal Regimen for Mycobacterium Abscessus Treatment | Pulmonary Disease Due to Mycobacteria (Diagnosis) | Recruiting |
| Phase 2 | |||
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory… | Extramedullary Disease in Multiple Myeloma | Recruiting |
| NCT06356571 | A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and… | Plasma Cell Myeloma Refractory | Recruiting |
| NCT05896228 | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With… | Refractory Multiple Myeloma | Recruiting |
| NCT07227311 | A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… | Multiple Myeloma | Recruiting |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and… | Relapsed/Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT05556746 | Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard… | Tuberculosis, Pulmonary | Active, Not Recruiting |
| NCT04883242 | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or… | Recurrent Multiple Myeloma | Active, Not Recruiting |
| NCT07485010 | Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase… | Mycobacterium Abscessus Pulmonary Disease | Not Yet Recruiting |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With… | Multiple Myeloma | Active, Not Recruiting |
| NCT04925193 | Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Active, Not Recruiting |
| NCT03500445 | Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly… | Myeloma | Active, Not Recruiting |
| NCT03828201 | Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and… | Tuberculosis, Multidrug-Resistant | Active, Not Recruiting |